5 oncology drugs get PBAC recommendation for PBS listing

The Pharmaceutical Benefits Advisory Committee has recommended new and extended PBS listings for several oncology drugs including treatments for prostate cancer, breast cancer, and gastrointestinal stromal tumour. At its July meeting the PBAC recommended the listing of darolutamide (Nubeqa, Bayer) for the treatment of patients with non-metastatic castration resistant prostate cancer (m0CRPC). Nivolumab (Opdivo) received ...

Already a member?

Login to keep reading.

© 2022 the limbic